How to Cite
Abstract
Coronary heart disease (CHD) is the leading cause of cardiovascular morbidity and mortality worldwide. The development of treatments for CHD is a significant focus of attention for researchers and clinical physicians, and in recent years traditional Chinese medicine (TCM) has played a key role in the treatment of CHD. TCM treats CHD based on the concept and characteristics of syndrome differentiation. Shexiang Baoxin Pill (SBP, 麝香保心丸) is a TCM formula widely used in East Asia for cardiovascular diseases. It can dilate coronary arteries, rapidly relieve angina pectoris symptoms, protect vascular endothelium, inhibit atherosclerosis, stabilize arterial plaques, reduce cardiovascular risk events, and promote therapeutic angiogenesis. SBP is composed of a mixture of TCM therapeutic agents and has demonstrated significant efficacy, few side effects, high patient acceptance, and high-cost performance. Translational research on SBP aims to provide robust evidence for its use as a complementary or alternative therapy for cardiovascular diseases, to identify its precise mechanisms of action, and to refine its clinical application for improved patient outcomes. This paper summarizes and analyzes the current translational and clinical research, and the pharmacological effects of SBP in the treatment of CHD, to provide a theoretical basis and reference for its further development and use in the treatment of CHD.